This study demonstrates that Ling-Gui-Zhu-Gan Decoction prevents MASLD, and its mechanism of action involves the regulation of gut microbiota and the modulation of lipid metabolism.
Abstract
Background The prevalence of metabolic dysfunction-associated steatotic liver disease (MASLD) has been continuously increasing. However, the pathogenesis of MASLD is quite complex and involves multiple factors, leading to a lack of targeted therapeutic drugs for MASLD. Ling-Gui-Zhu-Gan Decoction (LGZGD) has demonstrated significant hepatoprotective and lipid-lowering effects, yet its mechanism of action against MASLD remains incompletely understood. Methods In this study, we established a high-fat diet-induced MASLD rat model to investigate the pharmacological effects of LGZGD on MASLD from the perspectives of gut microbiota and lipidomics. Results Using UPLC-Q-TOF-MS analysis, we putatively identified 83 chemical components in LGZGD, primarily flavones and terpenoids, which may represent the key active constituents responsible for its ameliorative effects. In MASLD model rats, LGZGD treatment reduced the levels of TC, TG, AST, ALT, and LDL-C in both serum and liver tissue, while increasing HDL-C levels. Analysis of the gut microbiota revealed that LGZGD treatment increased the abundance of g__Collinsella and g__Prevotellaceae_UCG-003, and decreased the abundance of g__Faecalibaculum. Furthermore, LGZGD was found to regulate 831 lipids, primarily involved in metabolic pathways such as glycerophospholipid, glycerolipid, and sphingolipid metabolism. Conclusions This study demonstrates that LGZGD prevents MASLD, and its mechanism of action involves the regulation of gut microbiota and the modulation of lipid metabolism.
Metabolic dysfunction-associated steatotic liver disease (MASLD) represents a growing global health challenge, necessitating the discovery of safe and effective therapeutic agents from natural dietary sources. Zanthoxylum bungeanum Maxim. (huajiao), a widely consumed pharma-food, contains abundant alkaloids with re...
Wenyi Liang, Hengmin Yang, Yaqian Duan et al.· Food Science and Human Welln...· 0 citations
This integrative approach confirms that WZDP confers therapeutic benefits in MASLD through coordinated regulation of neuroactive ligand–receptor interaction, bile acid biosynthesis, phospholipase D signaling, and arginine–proline metabolism.
Metabolic dysfunction-associated steatohepatitis (MASH) is a progressive liver disease characterized by lipid metabolism dysregulation, insulin resistance, inflammation, and potential progression to severe liver conditions. Xiaochaihutang (XCHT), a traditional Chinese medicine, has been explored for its therapeutic pot...
Jia-Jia Yu, Zhi-Yuan Liu, Yan-Ping Li et al.· Antioxidants· 0 citations
ETHNOPHARMACOLOGICAL RELEVANCE
Cholestasis-induced liver diseases present with complex symptoms, exhibit significant individual variation in clinical treatment outcomes, and show diverse disease progression and prognoses, making them a key clinical focus in the field of hepatology. Zhizi Baipi Decoction (ZBP), derived...
H. Hai, Jing-Wen Mai, Jing-Yi Wang et al.· Journal of Ethnopharmacology· 0 citations
TMP combined with APS exerts enhanced anti-hepatic fibrosis effects compared with either monotherapy, and is associated with changes in gut microbiota composition, elevated fecal short-chain fatty acid levels, and reduced expression of hepatic TLR4/MyD88/NF-κB pathway-related molecules.
Yin-Jie Ma, Chao-Xing Wang, Xue Chen et al.· Frontiers in Pharmacology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.